Wealthcare Advisory Partners LLC Has $382,000 Position in Danaher Co. (NYSE:DHR)

Wealthcare Advisory Partners LLC lifted its position in Danaher Co. (NYSE:DHR) by 8.8% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,649 shares of the conglomerate’s stock after purchasing an additional 134 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Danaher were worth $382,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Banco Santander S.A. bought a new stake in shares of Danaher in the third quarter valued at about $683,000. First Citizens Bank & Trust Co. raised its stake in Danaher by 0.6% during the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after acquiring an additional 149 shares in the last quarter. Cercano Management LLC boosted its stake in shares of Danaher by 11.4% in the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock valued at $46,862,000 after purchasing an additional 20,715 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Danaher by 48.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after purchasing an additional 96,395 shares in the last quarter. Finally, Parkside Financial Bank & Trust boosted its position in Danaher by 4.8% in the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after buying an additional 142 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Danaher

In related news, Director Walter G. Lohr sold 3,289 shares of Danaher stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $251.15, for a total value of $826,032.35. Following the sale, the director now owns 14,129 shares of the company’s stock, valued at approximately $3,548,498.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Danaher news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now directly owns 116,202 shares in the company, valued at $28,304,483.16. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Walter G. Lohr sold 3,289 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $251.15, for a total transaction of $826,032.35. Following the transaction, the director now owns 14,129 shares in the company, valued at $3,548,498.35. The disclosure for this sale can be found here. Insiders have sold 103,984 shares of company stock valued at $25,997,094 in the last 90 days. 10.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently commented on DHR. Robert W. Baird increased their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Raymond James upped their price target on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Bank of America upped their price objective on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a report on Wednesday, April 24th. Finally, Citigroup boosted their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $267.31.

Danaher Price Performance

DHR opened at $251.48 on Friday. The company has a fifty day simple moving average of $248.15 and a 200 day simple moving average of $233.30. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The stock has a market cap of $186.27 billion, a P/E ratio of 42.62, a P/E/G ratio of 3.82 and a beta of 0.83. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same period in the previous year, the firm earned $2.36 EPS. Danaher’s quarterly revenue was down 2.6% compared to the same quarter last year. On average, research analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Friday, June 28th. Danaher’s payout ratio is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.